Bio-Rad Laboratories Class B
BIO.B
6 hedge funds and large institutions have $1.16M invested in Bio-Rad Laboratories Class B in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
0.04% less ownership
Funds ownership: 0.11% → 0.07% (-0.04%)
25% less funds holding
Funds holding: 8 → 6 (-2)
42% less capital invested
Capital invested by funds: $2M → $1.16M (-$837K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$675K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$17.8K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$10.9K |
BIO.B Hedge Fund Activity: Q4 2023 in Review
6 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class B (BIO.B) for Q4 2023, worth a combined $1.16M — down 42% from $2M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIO.B and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $675K sold.
- 6 institutional investors held Bio-Rad Laboratories Class B (BIO.B) as of Q4 2023, down from 8 in Q3 2023.
- Funds reported $1.16M of Bio-Rad Laboratories Class B stock for Q4 2023, down 42% quarter-over-quarter.
- 0 funds opened new Bio-Rad Laboratories Class B positions in Q4 2023 and 2 closed out, a net change of -2 holders.
- The largest Bio-Rad Laboratories Class B seller in Q4 2023 was Renaissance Technologies, an estimated $675K sold.
Based on aggregated 13F filings for Q4 2023.